Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy
NCT07311083 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2026-05-08
Summary
Triple-negative breast cancer (TNBC) is considered a tumor with a high risk of recurrence and metastasis and requires aggressive systemic therapy combining immunotherapy and chemotherapy. If the therapy leads to complete remission (pCR), this is prognostically beneficial for patients.
Studies demonstrating the influence of the microbiome on the development of cancer and on the efficacy and toxicity of immunotherapy and chemotherapy underscore the potential of targeted nutritional interventions. Current data from microbiome research indicate that a high-fiber, gut-healthy diet modulates the microbiota in such a way that the response to and toxicity of immunotherapy and chemotherapy could be improved.
The aim of this project is to translate these findings into clinical care. The study will investigate whether an online integrative oncology group training program with mind-body elements supports and is feasible for the implementation of a high-fiber diet in patients with TNBC undergoing neoadjuvant immunotherapy and chemotherapy. The program will be compared with a control group that receives a flyer with nutritional recommendations. If the feasibility of this complementary medicine approach can be demonstrated, a confirmatory study is planned to investigate the expected effect on the pathological complete remission of TNBC.
Conditions
- Microbiome
Interventions
- OTHER
-
switching to a high-fibre diet
The aim of the intervention is to support patients in implementing a high-fibre diet (20-30 g of fibre per day) before and during systemic therapy. A multi-professional team consisting of a specialist doctor, a qualified nutritionist and an MBM therapist ensures comprehensive support during lifestyle modification. While the nutritional counselling provides recommendations for optimising diet, the MBM intervention addresses behavioural factors such as motivation, self-efficacy expectations and dealing with barriers to action. In addition, the specialist provides advice on symptom management.
- OTHER
-
official dietary recommendations
providing official dietary recommendations and an educational training video based on these recommendations of the guidelines of the German Nutrition Society (DGE)
Sponsors & Collaborators
-
Karl and Veronica Carstens Foundation
collaborator OTHER -
Kliniken Essen-Mitte
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-01
- Primary Completion
- 2026-07-01
- Completion
- 2027-07-01
Countries
- Germany
Study Locations
More Related Trials
-
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer
NCT06175390 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast Cancer
NCT00870168 ·Status: COMPLETED ·Phase: NA
-
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
NCT06492759 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
NCT04584112 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT06246968 ·Status: RECRUITING ·Phase: PHASE1
-
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
NCT00193076 ·Status: COMPLETED ·Phase: PHASE2
-
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
NCT01022138 ·Status: TERMINATED ·Phase: PHASE2
-
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
NCT01629615 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
NCT01326481 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
NCT07017673 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
NCT02435680 ·Status: COMPLETED ·Phase: PHASE2
-
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
NCT05233696 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
NCT01732276 ·Status: UNKNOWN ·Phase: PHASE2
-
Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC
NCT04368468 ·Status: COMPLETED
-
A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
NCT01201265 ·Status: COMPLETED ·Phase: PHASE2
-
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer
NCT06910072 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
NCT00542191 ·Status: TERMINATED ·Phase: PHASE2
-
Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer
NCT00367250 ·Status: UNKNOWN ·Phase: PHASE1
-
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730 ·Status: RECRUITING ·Phase: PHASE3
-
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
NCT03135171 ·Status: COMPLETED ·Phase: PHASE1
-
BKM120 For Triple Negative Breast Cancer
NCT01790932 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
NCT03818685 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery
NCT00635245 ·Status: WITHDRAWN ·Phase: PHASE1
-
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
NCT06137651 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
NCT02768701 ·Status: COMPLETED ·Phase: PHASE2